CoChat

Precondensed Plasmid DNA enhances CAR-T cell generation via lipid nanoparticles

Pirrottina, Andrea, Renzi, Serena, Digiacomo, Luca, Giulimondi, Francesca, De Lorenzi, Valentina, Ghignoli, Samuele, Pesce, Luca, Cardarelli, Francesco, Mura, Francesco, Parisi, Giacomo, Buccini, Luca, Cassone, Chiara, Zingoni, Alessandra, Pozzi, Daniela, Caracciolo, Giulio · 2025 · ACS Omega
Cited by 4

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The advent of chimeric antigen receptor (CAR) T-cell therapy has introduced a novel and personalized approach to cancer treatment. Despite its promise, the challenge of developing a system that bypasses the need for viral vectors remains significant, particularly in terms of achieving a clinical efficacy and sustained durability. To address these challenges, lipid nanoparticles (LNPs) produced through advanced microfluidic technology have been recently utilized to encapsulate plasmid DNA (pDNA) encoding CAR receptors. However, the intrinsic challenges associated with pDNA encapsulation, along with the critical requirement for efficient expression, remain substantial obstacles. Here, we show that incorporating DNA-condensing agents into the microfluidic manufacturing of LNPs effectively overcomes these limitations. Briefly, we conducted a preliminary investigation to characterize LNPs with and without the commercial condensing agent P3000-Reagent (PR), focusing on their physicochemical properties and scrutinizing the biological outcomes primarily in the HEK-293 cell line. Our results demonstrated that precondensation of the pDNA with PR differentially increased the transfection efficiency of the tested formulations, whereas confocal microscopy indicated reduced lysosomal colocalization and major nuclear localization. Finally, PR was found to enhance LNP efficiency upon multiple administrations to the immortalized T-lymphocyte Jurkat cell line, enabling the delivery of both a luciferase reporter gene and a functional CAR-encoding plasmid. Overall, these findings underscore the great potential of introducing DNA-condensing agents into the LNP preparation process, especially for systems designed for challenging delivery applications, such as multiadministration transfection protocols.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsomega.5c04308

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 42

  1. June, 2018, Chimeric Antigen Receptor Therapy, N. Engl. J. Med., 379, 64, 10.1056/NEJMra1706169 · DOI · Paper page
  2. Butt, 2022, Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review, Genes, 13, 1370, 10.3390/genes13081370 · DOI · Paper page
  3. van der Loo, 2016, Progress and challenges in viral vector manufacturing, Hum. Mol. Genet., 25, R42, 10.1093/hmg/ddv451 · DOI · Paper page
  4. Quagliarini, 2021, Microfluidic formulation of DNA-loaded multicomponent lipid nanoparticles for gene delivery, Pharmaceutics, 13, 1292, 10.3390/pharmaceutics13081292 · DOI
  5. Samaridou, 2020, Lipid nanoparticles for nucleic acid delivery: Current perspectives, Adv. Drug Deliv. Rev., 154, 37, 10.1016/j.addr.2020.06.002 · DOI · Paper page
  6. Krammer, 2020, SARS-CoV-2 vaccines in development, Nature, 586, 516, 10.1038/s41586-020-2798-3 · DOI · Paper page
  7. Quagliarini, 2022, Mechanistic Insights into the Superior DNA Delivery Efficiency of Multicomponent Lipid Nanoparticles: An In Vitro and In Vivo Study, ACS Appl. Mater. Interfaces, 14, 56666, 10.1021/acsami.2c20019 · DOI
  8. Cui, 2022, Efficient delivery of DNA using lipid nanoparticles, Pharmaceutics, 14, 1698, 10.3390/pharmaceutics14081698 · DOI
  9. Van de Vyver, 2022, Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics, Adv. Drug Delivery Rev., 181, 114041, 10.1016/j.addr.2021.114041 · DOI
  10. Giulimondi, 2024, Optimizing Transfection Efficiency in CAR-T Cell Manufacturing through Multiple Administrations of Lipid-Based Nanoparticles, ACS Appl. Bio Mater., 7, 3746, 10.1021/acsabm.4c00103 · DOI
  11. Martins, 2004, Nuclear Matrix Interactions at the Human Protamine Domain: A Working Model of Potentiation, J. Biol. Chem., 279, 51862, 10.1074/jbc.M409415200 · DOI
  12. Cornetta, 1989, Protamine sulfate as an effective alternative to Polybrene in retroviral-mediated gene-transfer: implications for human gene therapy, J. Virol. Methods, 23, 187, 10.1016/0166-0934(89)90132-8 · DOI
  13. Caracciolo, 2011, Factors Determining the Superior Performance of Lipid/DNA/Protammine Nanoparticles over Lipoplexes, J. Med. Chem., 54, 4160, 10.1021/jm200237p · DOI
  14. Wang, 2018, Systematic screening of commonly used commercial transfection reagents towards efficient transfection of single-stranded oligonucleotides, Molecules, 23, 2564, 10.3390/molecules23102564 · DOI · Paper page
  15. Nakamura, 2022, Importance of Process Parameters Influencing the Mean Diameters of siRNA-Containing Lipid Nanoparticles (LNPs) on the in Vitro Activity of Prepared LNPs, Biol. Pharm. Bull., 45, 497, 10.1248/bpb.b21-01016 · DOI
  16. Engin, 2017, Mechanistic understanding of nanoparticles’ interactions with extracellular matrix: the cell and immune system, Part. Fibre Toxicol., 14, 22, 10.1186/s12989-017-0199-z · DOI · Paper page
  17. Gilbert, 2024, Evolution of the structure of lipid nanoparticles for nucleic acid delivery: From in situ studies of formulation to colloidal stability, J. Colloid Interface Sci., 660, 66, 10.1016/j.jcis.2023.12.165 · DOI
  18. Marchini, 2010, Tailoring lipoplex composition to the lipid composition of plasma membrane: a Trojan horse for cell entry?, Langmuir, 26, 13867, 10.1021/la1023899 · DOI
  19. Warga, 2023, Transcriptomic analysis of the innate immune response to in vitro transfection of plasmid DNA, Mol. Ther. Nucleic Acids, 31, 43, 10.1016/j.omtn.2022.11.025 · DOI
  20. Tan, 2021, HEK293 cell line as a platform to produce recombinant proteins and viral vectors, Front. Bioeng. Biotechnol., 9, 796991, 10.3389/fbioe.2021.796991 · DOI · Paper page
  21. Dekevic, 2022, Statistical experimental designs to optimize the transient transfection of HEK 293T cells and determine a transfer criterion from adherent cells to larger-scale cell suspension cultures, J. Biotechnol., 346, 23, 10.1016/j.jbiotec.2022.01.004 · DOI
  22. Gilleron, 2013, Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape, Nat. Biotechnol., 31, 638, 10.1038/nbt.2612 · DOI · Paper page
  23. Sfera, 2022, Psychotropic drugs interaction with the lipid nanoparticle of COVID-19 mRNA therapeutics, Front. Pharmacol., 13, 995481, 10.3389/fphar.2022.995481 · DOI
  24. Rennick, 2021, Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics, Nat. Nanotechnol., 16, 266, 10.1038/s41565-021-00858-8 · DOI · Paper page
  25. Montani, 2015, Getting the most from gene delivery by repeated DNA transfections, Appl. Phys. Lett., 106, 233701, 10.1063/1.4922288 · DOI
  26. Abraham, 2004, Jurkat T cells and development of the T-cell receptor signalling paradigm, Nat. Rev. Immunol., 4, 301, 10.1038/nri1330 · DOI · Paper page
  27. Bloemberg, 2020, A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells, Mol. Ther.--Methods Clin. Dev., 16, 238, 10.1016/j.omtm.2020.01.012 · DOI
  28. Irvine, 2020, Enhancing cancer immunotherapy with nanomedicine, Nat. Rev. Immunol., 20, 321, 10.1038/s41577-019-0269-6 · DOI · Paper page
  29. Billingsley, 2020, Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering, Nano Lett., 20, 1578, 10.1021/acs.nanolett.9b04246 · DOI · Paper page
  30. Billingsley, 2022, Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells, Nano Lett., 22, 533, 10.1021/acs.nanolett.1c02503 · DOI · Paper page
  31. Prazeres, 2023, Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells, Int. J. Nanomed., 18, 5891, 10.2147/ijn.s424723 · DOI
  32. Sun, 2023, Structure and function of cationic and ionizable lipids for nucleic acid delivery, Pharm. Res., 40, 27, 10.1007/s11095-022-03460-2 · DOI · Paper page
  33. Cárdenas, 2023, Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery, Curr. Opin. Colloid Interface Sci., 66, 101705, 10.1016/j.cocis.2023.101705 · DOI · Paper page
  34. Felgner, 1987, Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. U.S.A., 84, 7413, 10.1073/pnas.84.21.7413 · DOI · Paper page
  35. Pozzi, 2012, Transfection efficiency boost of cholesterol-containing lipoplexes, Biochim. Biophys. Acta, Biomembr., 1818, 2335, 10.1016/j.bbamem.2012.05.017 · DOI
  36. Hosseini, 2019, Cholesterol-rich lipid-mediated nanoparticles boost of transfection efficiency, utilized for gene editing by CRISPR–Cas9, Int. J. Nanomed., 14, 4353, 10.2147/ijn.s199104 · DOI
  37. Weigel, 1981, Temperature dependence of endocytosis mediated by the asialoglycoprotein receptor in isolated rat hepatocytes. Evidence for two potentially rate-limiting steps, J. Biol. Chem., 256, 2615, 10.1016/S0021-9258(19)69656-0 · DOI · Paper page
  38. Cardarelli, 2016, The intracellular trafficking mechanism of Lipofectamine-based transfection reagents and its implication for gene delivery, Sci. Rep., 6, 25879, 10.1038/srep25879 · DOI · Paper page
  39. Chatterjee, 2024, Endosomal escape: A bottleneck for LNP-mediated therapeutics, Proc. Natl. Acad. Sci. U.S.A., 121, 10.1073/pnas.2307800120 · DOI · Paper page
  40. Zhao, 2012, Transfecting the hard-to-transfect lymphoma/leukemia cells using a simple cationic polymer nanocomplex, J. Contr. Release, 159, 104, 10.1016/j.jconrel.2012.01.007 · DOI · Paper page
  41. Carrasco-Padilla, 2023, T cell activation and effector function in the human Jurkat T cell model, Methods Cell Biol., 178, 25, 10.1016/bs.mcb.2022.09.012 · DOI
  42. Caruso, 2019, Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function, J. Neuro Oncol., 145, 429, 10.1007/s11060-019-03311-y · DOI

Cited by

Metadata

Authors
Pirrottina, A., Renzi, S., Digiacomo, L., Giulimondi, F., De Lorenzi, V., Ghignoli, S., Pesce, L., Cardarelli, F., Mura, F., Parisi, G., Buccini, L., Cassone, C., Zingoni, A., Pozzi, D., & Caracciolo, G.
Affiliations
  • Sapienza University of Rome , , ,
  • Scuola Normale Superiore , , ,
Venue
ACS Omega
Published
2025-07-04
Volume
10
Issue
27
Pages
29804-29814
ISSN
2470-1343
Cited by
4
References
5
Language
en
Funders
Ministero dell'Universit? e della Ricerca (CUP: B53C22004000006, PNRR - ECS00000017, PNRR - M4C2I1.3, PNRR - PE_00000019, PON TITAN 2014-2020)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.